Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy

医学 内科学 丙型肝炎 丙型肝炎病毒 人口 免疫学 病毒 环境卫生
作者
Jason Grebely,Gregory J. Dore,Frederick L. Altice,Brian Conway,Alain H. Litwin,Brianna L. Norton,Olav Dalgård,Edward Gane,Oren Shibolet,Ronald Nahass,Anne F. Luetkemeyer,Cheng‐Yuan Peng,David Iser,Isaias Noel Gendrano,Michelle M. Kelly,Peggy Hwang,Ernest Asante‐Appiah,Barbara Haber,Eliav Barr,Michael Robertson,Heather Platt
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:175 (9): 1221-1229 被引量:9
标识
DOI:10.7326/m21-4119
摘要

Background: Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. Objective: To evaluate the rate of HCV reinfection for 3 years after successful treatment among people receiving opioid agonist therapy (OAT). Design: A 3-year, long-term, extension study of persons enrolled in the CO-STAR (Hepatitis C Patients on Opioid Substitution Therapy Antiviral Response) study (ClinicalTrials.gov: NCT02105688). Setting: 55 clinical trial sites in 13 countries. Patients: Aged 18 years and older with chronic HCV infection with genotypes 1, 4, or 6 receiving stable OAT. Intervention: No treatments were administered. Measurements: Serum samples were assessed for HCV reinfection. Urine drug screening was performed. Results: Among 296 participants who received treatment, 286 were evaluable for reinfection and 199 were enrolled in the long-term extension study. The rate of HCV reinfection was 1.7 [95% CI, 0.8 to 3.0] per 100 person-years; 604 person-years of follow-up). A higher rate of reinfection was seen among people with recent injecting drug use (1.9 [95% CI, 0.5 to 4.8] per 100 person-years; 212 person-years). Ongoing drug use and injecting drug use were reported by 59% and 21% of participants, respectively, at the 6-month follow-up visit and remained stable during 3 years of follow-up. Limitations: Participants were required to be 80% adherent to OAT at baseline and may represent a population with higher stability and lower risk for HCV reinfection. Rate of reinfection may be underestimated because all participants did not continue in the long-term extension study; whether participants who discontinued were at higher risk for reinfection is unknown. Conclusion: Reinfection with HCV was low but was highest in the first 24 weeks after treatment completion and among people with ongoing injecting drug use and needle–syringe sharing. Primary Funding Source: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
windyhill完成签到,获得积分10
2秒前
鳗鱼紫萱完成签到,获得积分10
3秒前
我必定发nature关注了科研通微信公众号
3秒前
GG波波发布了新的文献求助10
4秒前
华仔应助晴云采纳,获得10
6秒前
快乐小狗完成签到 ,获得积分10
6秒前
珞珈完成签到,获得积分10
6秒前
Ya完成签到,获得积分10
6秒前
谦让文昊完成签到,获得积分10
7秒前
小红勇闯科研界完成签到,获得积分10
9秒前
科研通AI2S应助长安采纳,获得10
11秒前
11秒前
12秒前
Amber完成签到,获得积分10
12秒前
12秒前
teborlee完成签到,获得积分10
13秒前
xinxin完成签到,获得积分10
13秒前
SYLH应助鳗鱼鸽子采纳,获得10
13秒前
YY完成签到,获得积分10
14秒前
老德完成签到,获得积分10
14秒前
靓丽的熠彤完成签到,获得积分10
15秒前
深情海秋完成签到,获得积分10
15秒前
16秒前
歇洛克完成签到,获得积分10
17秒前
cao完成签到,获得积分20
17秒前
为你博弈完成签到,获得积分10
18秒前
18秒前
于情信芳完成签到,获得积分10
18秒前
庚小马发布了新的文献求助10
18秒前
淡然妙竹发布了新的文献求助10
19秒前
炒栗子发布了新的文献求助10
19秒前
晴云发布了新的文献求助10
19秒前
20秒前
PHW完成签到,获得积分10
20秒前
monly应助Fin2046采纳,获得30
21秒前
Hello应助JJG采纳,获得10
21秒前
李健的小迷弟应助WJH采纳,获得10
21秒前
23秒前
ty发布了新的文献求助10
23秒前
刘逸藩完成签到,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048